Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
- Pfizer Japan Files Public Knowledge-based Application for Diflucan
June 20, 2011
- US CRO to Provide Financial Support to Codevelopment Partner of MediBIC
June 20, 2011
- Amgen to Focus on 4 Fields Including Cancer Taking Advantage of Its Strength in Biotech
June 20, 2011
- Novartis Files Public Knowledge-based Applications for Add'l Indications for 3 More Products
June 20, 2011
- Takeda Presents PI Data on MLN4924 at ASCO
June 20, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
- Eisai's Achievements Most Conspicuous in FY2011 Settlement of Accounts: Nomura Securities
June 13, 2011
- IMUC Becomes 18th Licensee for POTELLIGENT Technology: BioWa
June 13, 2011
- Kyowa Hakko Bio Establishes Efficient Amino Acid Derivative Manufacturing Process
June 13, 2011
- Teijin: Bonalon, Onealfa Contribute to Growth in Sales
June 13, 2011
- DSP to Inaugurate Global Oncology Business Development Office
June 13, 2011
- NanoCarrier's Micelle Technology Moves Closer to Patent in Japan
June 13, 2011
- Meiji HD: Pharmaceuticals Segment's Sales Up 2.3%
June 13, 2011
- JPMA to Issue Serious Warning against MSD over PC Violations
June 13, 2011
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…